CN105147651A - 治疗眼科疾病的醌类的制剂 - Google Patents

治疗眼科疾病的醌类的制剂 Download PDF

Info

Publication number
CN105147651A
CN105147651A CN201510490746.XA CN201510490746A CN105147651A CN 105147651 A CN105147651 A CN 105147651A CN 201510490746 A CN201510490746 A CN 201510490746A CN 105147651 A CN105147651 A CN 105147651A
Authority
CN
China
Prior art keywords
disease
formulation
formula
hydroxy
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510490746.XA
Other languages
English (en)
Chinese (zh)
Inventor
G·M·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edison Phamaceuticals Inc
Original Assignee
Edison Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Phamaceuticals Inc filed Critical Edison Phamaceuticals Inc
Publication of CN105147651A publication Critical patent/CN105147651A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201510490746.XA 2010-04-27 2011-04-26 治疗眼科疾病的醌类的制剂 Pending CN105147651A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32854610P 2010-04-27 2010-04-27
US61/328,546 2010-04-27
US39369310P 2010-10-15 2010-10-15
US61/393,693 2010-10-15
CN2011800317444A CN102985083A (zh) 2010-04-27 2011-04-26 治疗眼科疾病的醌类的制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800317444A Division CN102985083A (zh) 2010-04-27 2011-04-26 治疗眼科疾病的醌类的制剂

Publications (1)

Publication Number Publication Date
CN105147651A true CN105147651A (zh) 2015-12-16

Family

ID=44861894

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510490746.XA Pending CN105147651A (zh) 2010-04-27 2011-04-26 治疗眼科疾病的醌类的制剂
CN2011800317444A Pending CN102985083A (zh) 2010-04-27 2011-04-26 治疗眼科疾病的醌类的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011800317444A Pending CN102985083A (zh) 2010-04-27 2011-04-26 治疗眼科疾病的醌类的制剂

Country Status (13)

Country Link
US (2) US20130109759A1 (https=)
EP (1) EP2563352A4 (https=)
JP (2) JP5902673B2 (https=)
CN (2) CN105147651A (https=)
AU (1) AU2011245384C1 (https=)
BR (1) BR112012027543A8 (https=)
CA (1) CA2797581A1 (https=)
EA (1) EA201201465A1 (https=)
MX (1) MX337594B (https=)
MY (1) MY183449A (https=)
SG (2) SG185046A1 (https=)
WO (1) WO2011137126A1 (https=)
ZA (1) ZA201208535B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
AU2015364640B2 (en) 2014-12-16 2020-08-13 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3390377B1 (en) 2015-12-16 2026-03-25 PTC Therapeutics, Inc. Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2019070917A1 (en) * 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
KR20210076956A (ko) 2018-10-17 2021-06-24 피티씨 테라퓨틱스, 인크. α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온
CN114126640B (zh) * 2019-05-28 2024-10-29 爱儿安制药有限公司 治疗视网膜病变的组合物和方法
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona
WO2025231245A1 (en) * 2024-05-02 2025-11-06 Stealth Biotherapeutics Inc. Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
US20070066541A1 (en) * 2005-09-16 2007-03-22 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278085B2 (en) * 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP2344142B1 (en) * 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
US20070066541A1 (en) * 2005-09-16 2007-03-22 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TABRIZI S J ET AL: "PRIMARY AND SECONDARY DEFICIENCIES OF THE MITOCHONDRIAL RESPIRATORY CHAIN", 《NEUROLOGIST,WLLIAMS AND WILKINS,BALTIMORE,MD,US》 *

Also Published As

Publication number Publication date
BR112012027543A2 (pt) 2019-05-28
JP2013525443A (ja) 2013-06-20
CN102985083A (zh) 2013-03-20
EA201201465A1 (ru) 2013-04-30
ZA201208535B (en) 2016-06-29
EP2563352A1 (en) 2013-03-06
AU2011245384A1 (en) 2012-12-06
MY183449A (en) 2021-02-18
US20130109759A1 (en) 2013-05-02
US20170354618A1 (en) 2017-12-14
SG10201801321XA (en) 2018-04-27
AU2011245384B2 (en) 2016-02-18
JP2016106144A (ja) 2016-06-16
JP6266674B2 (ja) 2018-01-24
MX2012012518A (es) 2012-12-17
AU2011245384C1 (en) 2016-09-01
EP2563352A4 (en) 2013-11-13
MX337594B (es) 2016-03-11
BR112012027543A8 (pt) 2019-12-03
WO2011137126A1 (en) 2011-11-03
CA2797581A1 (en) 2011-11-03
SG185046A1 (en) 2012-12-28
JP5902673B2 (ja) 2016-04-13

Similar Documents

Publication Publication Date Title
AU2011245384B9 (en) Formulations of quinones for the treatment of ophthalmic diseases
AU2011245384B2 (en) Formulations of quinones for the treatment of ophthalmic diseases
US20100273892A1 (en) Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
EP2424495B1 (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US20120136048A1 (en) Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
HK1168028B (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
HK1168028A (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American California

Applicant after: Biological Electronic Technology Co., Ltd.

Address before: American California

Applicant before: Edison Pharmaceuticals Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151216